Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fortress Biotech

1.74
+0.02311.34%
Volume:93.70K
Turnover:161.45K
Market Cap:51.48M
PE:-0.65
High:1.78
Open:1.75
Low:1.69
Close:1.72
Loading ...

Press Release: Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Dow Jones
·
13 Nov 2024

Mustang Bio Inc - Extension Granted to Meet $1.00 Bid Price Requirement Through Jan 31, 2025

THOMSON REUTERS
·
12 Nov 2024

Mustang Bio Receives Positive Listing Determination From Nasdaq

THOMSON REUTERS
·
12 Nov 2024

Checkpoint Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview

Reuters
·
09 Nov 2024

Avenue Therapeutics Inc expected to post a loss of 94 cents a share - Earnings Preview

Reuters
·
09 Nov 2024

Fortress Biotech Inc expected to post a loss of 59 cents a share - Earnings Preview

Reuters
·
08 Nov 2024

Mustang Bio - Mb-108 (Hsv-1 Oncolytic Virus) Is Active and Well Tolerated in Patients With Recurrent Glioblastoma in Ongoing Phase 1 Clinical Trial

THOMSON REUTERS
·
07 Nov 2024

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for Mb-108 (Hsv-1 Oncolytic Virus) to Treat Malignant Glioma

THOMSON REUTERS
·
07 Nov 2024

FDA approves Journey Medical's drug for long-term skin condition

Reuters
·
04 Nov 2024

Journey Medical Corp - Initial Supply of Emrosi Expected in Q1 or Q2 2025

THOMSON REUTERS
·
04 Nov 2024

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 Mg) for the Treatment of Rosacea

THOMSON REUTERS
·
04 Nov 2024

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

GlobeNewswire
·
04 Nov 2024

Fortress Biotech Insiders Placed Bullish Bets Worth US$4.49m

Simply Wall St.
·
31 Oct 2024

Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry

Simply Wall St.
·
29 Oct 2024

Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares

GuruFocus.com
·
26 Oct 2024

BRIEF-Highbridge Capital Management, Llc Reports 9% Passive Stake In Fortress Biotech, Inc. As Of Sept 30 - SEC Filing

Reuters
·
25 Oct 2024

Highbridge Capital Management, Llc Reports 9% Passive Stake in Fortress Biotech, Inc. as of Sept 30 - SEC Filing

THOMSON REUTERS
·
25 Oct 2024